Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023855 · ClinicalTrials.gov registry record · Phase 1
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00023855: Completed Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT00023855 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023855, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining PS-341 and doxorubicin in treating patients who have advanced solid tumors.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Phase | Phase 1 |
What the finished NCT00023855 record still lists
NCT00023855 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00023855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00023855 about?
NCT00023855 is a clinical study titled "PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining PS-341 and doxorubicin in treating patients who have advanced solid tumors.
What is the current status of trial NCT00023855?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-06.
What interventions are being tested in trial NCT00023855?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00023855?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia